Show simple item record

AuthorRahhal, Alaa
AuthorNajim, Mostafa
AuthorAljundi, Amer Hussein
AuthorMahfouz, Ahmed
AuthorAlyafei, Sumaya Mehdar
AuthorAwaisu, Ahmed
AuthorHabib, Mhd, Baraa
AuthorObeidat, Ibrahim
AuthorFaisal, Mohanad Mohammed
AuthorAlanzi, Meshaal Ali
AuthorNair, Arun Prabhakaran
AuthorElhassan, Areeg
AuthorAl-Dushain, Abdullah
AuthorAbdelmajid, Alaaeldin Abdelmajid
AuthorAbdelgader, Ahmed Elfadil
AuthorMoursi, Ahmed Mahmoud Ahmed
AuthorAlharafsheh, Ahmad Eid Nazzal
AuthorKamar, Mohd Ragheb Abou
AuthorGoravey, Wael
AuthorOmar, Amr Salah
AuthorAbukhattab, Mohammed
AuthorKhatib, Mohamad Yahya
AuthorMohamedali, Mohamed Gaafar
AuthorAlMaslamani, Muna A. Rahman
AuthorAlemadi, Samar
Available date2022-12-15T07:16:19Z
Publication Date2022
Publication NameMedicine (United States)
ResourceScopus
URIhttp://dx.doi.org/10.1097/MD.0000000000030843
URIhttp://hdl.handle.net/10576/37272
AbstractIntroduction: Colchicine acts upstream in the cytokines cascade by inhibiting the nod-like receptor protein 3 (NLRP3) inflammasome while interleukin 6 (IL-6) receptor antagonists, such as tocilizumab, block the end result of the cytokines cascade. Hence, adding colchicine to tocilizumab with the aim of blocking the early and end products of the cytokines cascade, might reduce the risk of developing cytokine storm. Methods and analysis: We aim to conduct an open-label randomized controlled trial to evaluate the efficacy and safety of adding colchicine to tocilizumab among patients with severe COVID-19 pneumonia to reduce the rate of invasive mechanical ventilation and mortality. We will include patients with severe COVID-19 pneumonia who received tocilizumab according to our local guidelines. Enrolled patients will be then randomized in 1:1 to colchicine versus no colchicine. Patients will be followed up for 30 days. The primary outcome is the rate of invasive mechanical ventilation and will be determined using Cox proportional hazard model. Discussion: Given colchicine's ease of use, low cost, good safety profile, and having different anti-inflammatory mechanism of action than other IL-6 blockade, colchicine might serve as a potential anti-inflammatory agent among patients with severe COVID-19 pneumonia. This study will provide valuable insights on the use of colchicine in severe COVID-19 when added to IL-6 antagonists. Ethics and dissemination: The Medical Research Center and Institutional Review Board at Hamad Medical Corporation in Qatar approved the study protocol (MRC-01-21-299). Results of the analysis will be submitted for publication in a peer-reviewed journal. 2022 Lippincott Williams and Wilkins. All rights reserved.
Languageen
PublisherLippincott Williams and Wilkins
Subjectcolchicine
COVID-19
IL-6 antagonists
severe pneumonia
tocilizumab
TitleAdding colchicine to tocilizumab in hospitalized patients with severe COVID-19 pneumonia: An open-label randomized controlled trial
TypeArticle
PaginationE30618
Issue Number39
Volume Number101
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record